Global Bio-pharma Market By Type (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, and Purified Proteins), By Application (Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, and Inflammatory and Infectious Diseases), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029
- 136100
- 16-Dec
- PDF/PPT/Word
-
Report Details
The report on Bio-pharma Market offers in-depth analysis of market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report includes the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global bio-pharma market is segmented on the basis of Type, Application, and geography.
The global Bio-pharma market is estimated to be US$ XX.X Mn in 2019 and is projected to increase significantly at a CAGR of x.x% from 2020 to 2028.Global Bio-pharma Market Scope:
By Type, the market is segmented into Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, and Purified Proteins. By Application, the market is divided into Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, and Inflammatory and Infectious Diseases.
Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Pfizer, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Sanofi Amgen, AbbVie, Merck & Co., Biogen Idec, Bayer AG, Eli Lilly and Company, Novartis AG GlaxoSmithKline Plc, Bristol-Myers Squibb Company, AstraZeneca PLC, and Abbott Laboratories.
Key Market Segments
Type
Monoclonal Antibodies
Recombinant Proteins
Granulocyte-Colony Stimulating Factor (G-CSF)
Interferons
Recombinant Human Insulin
Erythropoietin
Vaccines
Growth Hormones
Purified ProteinsApplication
Metabolic Disorders
Oncology
Neurological Disorders
Cardiovascular Diseases
Inflammatory and Infectious DiseasesKey Market Players included in the report:
Pfizer
F. Hoffmann-La Roche AG
Johnson & Johnson Services
Sanofi Amgen
AbbVie
Merck & Co.
Biogen Idec
Bayer AG
Eli Lilly and Company
Novartis AG GlaxoSmithKline Plc
Bristol-Myers Squibb Company
AstraZeneca PLC
Abbott LaboratoriesReasons to Get this Report:
In an insight outlook, this research report has dedicated to several quantities of analysis industry research (global industry trends) and Bio-pharma Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Bio-pharma Market; high-growth regions; and market drivers, restraints, and also market chances.
The analysis covers Bio-pharma Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Bio-pharma Market across sections such as also Application and representatives.
Additionally, the analysis also has a comprehensive review of the crucial players on the Bio-pharma Market together side their company profiles, SWOT analysis, latest advancements, and business plans.
The analysis objectives of the report are:
To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
To know the Bio-pharma Market by pinpointing its many subsegments.
To profile the important players and analyze their growth plans.
To endeavor the amount and value of Bio-pharma sub-markets, depending on key regions (various vital states).
To analyze Bio-pharma Market concerning growth trends, prospects, and also their participation in the entire sector.
To examine and study the Bio-pharma Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2014 to 2019, and also prediction to 2028.
Primary worldwide Bio-pharma Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market. -
Table Of Content
1. Bio-pharma Market Introduction
1.1. Definition
1.2. Taxonomy
1.3. Research Scope2. Executive Summary2.1. Key Findings by Major Segments
2.2. Top strategies by Major Players3. Global Bio-pharma Market Overview3.1. Bio-pharma Market Dynamics
3.1.1. Drivers
3.1.2. Opportunities
3.1.3. Restraints
3.1.4. Challenges 3.2. PESTLE Analysis
3.3. Opportunity Map Analysis
3.4. PORTER’S Five Forces Analysis
3.5. Market Competition Scenario Analysis
3.6. Product Life Cycle Analysis
3.7. Opportunity Orbits
3.8. Production Analysis by Region/Company
3.9. Industry chain Analysis
3.10. Marketing Strategy4. Global Bio-pharma Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-20284.1. Global Bio-pharma Market Analysis by Type: Introduction
4.2. Market Size and Forecast by Region
4.3. Monoclonal Antibodies4.4. Recombinant Proteins
4.5. Granulocyte-Colony Stimulating Factor (G-CSF)
4.6. Interferons
4.7. Recombinant Human Insulin
4.8. Erythropoietin
4.9. Vaccines
4.10. Growth Hormones
4.11. Purified Proteins5. Global Bio-pharma Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
5.1. Global Bio-pharma Market Analysis by Application: Introduction
5.2. Market Size and Forecast by Region
5.3. Metabolic Disorders5.4. Oncology
5.5. Neurological Disorders
5.6. Cardiovascular Diseases
5.7. Inflammatory and Infectious Diseases6. Global Bio-pharma Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
6.1. North America
6.1.1. North America Bio-pharma Market: Regional Trend Analysis
6.1.1.1. US
6.1.1.2. Canada
6.1.1.3. Mexico6.2.1. Europe
6.2.1. Europe Bio-pharma Market: Regional Trend Analysis
6.2.1.1. Germany
6.2.1.2. France
6.2.1.3. UK
6.2.1.4. Russia
6.2.1.5. Italy
6.2.1.6. Spain
6.2.1.7. Rest of Europe6.3. Asia-Pacific
6.3.1. Asia-Pacific Bio-pharma Market: Regional Trend Analysis
6.3.1.1. China
6.3.1.2. Japan
6.3.1.3. Korea
6.3.1.4. India
6.3.1.5. Rest of Asia-Pacific6.4. Latin America
6.4.1. Latin America Bio-pharma Market: Regional Trend Analysis
6.4.1.1. Brazil
6.4.1.2. Argentina
6.4.1.3. Rest of Latin America6.5. Middle East and Africa
6.5.1. Middle East and Africa Bio-pharma Market: Regional Trend Analysis
6.5.1.1. GCC
6.5.1.2. South Africa
6.5.1.3. Israel
6.5.1.4. Rest of MEA
7. Global Bio-pharma Market Competitive Landscape, Market Share Analysis, and Company Profiles7.1. Market Share Analysis
7.2. Company Profiles
7.3. Pfizer7.3.1. Company Overview
7.3.2. Financial Highlights
7.3.3. Product Portfolio
7.3.4. SWOT Analysis
7.3.5. Key Strategies and Developments 7.4. F. Hoffmann-La Roche AG7.4.1. Company Overview
7.4.2. Financial Highlights
7.4.3. Product Portfolio
7.4.4. SWOT Analysis
7.4.5. Key Strategies and Developments 7.5. Johnson & Johnson Services7.5.1. Company Overview
7.5.2. Financial Highlights
7.5.3. Product Portfolio
7.5.4. SWOT Analysis
7.5.5. Key Strategies and Developments 7.6. Sanofi Amgen7.6.1. Company Overview
7.6.2. Financial Highlights
7.6.3. Product Portfolio
7.6.4. SWOT Analysis
7.6.5. Key Strategies and Developments 7.7. AbbVie7.7.1. Company Overview
7.7.2. Financial Highlights
7.7.3. Product Portfolio
7.7.4. SWOT Analysis
7.7.5. Key Strategies and Developments 7.8. Merck & Co.7.8.1. Company Overview
7.8.2. Financial Highlights
7.8.3. Product Portfolio
7.8.4. SWOT Analysis
7.8.5. Key Strategies and Developments 7.9. Biogen Idec7.9.1. Company Overview
7.9.2. Financial Highlights
7.9.3. Product Portfolio
7.9.4. SWOT Analysis
7.9.5. Key Strategies and Developments 7.10. Bayer AG7.10.1. Company Overview
7.10.2. Financial Highlights
7.10.3. Product Portfolio
7.10.4. SWOT Analysis
7.10.5. Key Strategies and Developments 7.11. Eli Lilly and Company7.11.1. Company Overview
7.11.2. Financial Highlights
7.11.3. Product Portfolio
7.11.4. SWOT Analysis
7.11.5. Key Strategies and Developments 7.12. Novartis AG GlaxoSmithKline Plc7.12.1. Company Overview
7.12.2. Financial Highlights
7.12.3. Product Portfolio
7.12.4. SWOT Analysis
7.12.5. Key Strategies and Developments 7.13. Bristol-Myers Squibb Company7.13.1. Company Overview
7.13.2. Financial Highlights
7.13.3. Product Portfolio
7.13.4. SWOT Analysis
7.13.5. Key Strategies and Developments 7.14. AstraZeneca PLC7.14.1. Company Overview
7.14.2. Financial Highlights
7.14.3. Product Portfolio
7.14.4. SWOT Analysis
7.14.5. Key Strategies and Developments 7.15. Abbott Laboratories7.15.1. Company Overview
7.15.2. Financial Highlights
7.15.3. Product Portfolio
7.15.4. SWOT Analysis
7.15.5. Key Strategies and Developments8. Assumptions and Acronyms
9. Research Methodology
10. Contact -
Inquiry Before Buying
-
Request Sample
